Poland· PL-100445839
Supemtek Tetra
A influenza, inaktiviert, spalt/split virus oder oberflächen-antigen product containing czterowalentna szczepionka przeciw grypie (rekombinowana, przygotowana w hodowli komórkowej), registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen is registered in 11 of 19 countries.
Countries holding a registration under ATC J07BB02 (influenza, inaktiviert, spalt/split virus oder oberflächen-antigen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen · ATC J07BB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Czterowalentna szczepionka przeciw grypie (rekombinowana, przygotowana w hodowli komórkowej)
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- J07BB02
- ATC class
- Influenza, inaktiviert, Spalt/Split Virus oder Oberflächen-Antigen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 6
- gtin05909991452339
- gtin05909991452353
- gtin05909991452377
- gtin05909991452384
- gtin05909991452346
- gtin05909991452360
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BB02
Influenza, inaktiviert, spalt/split virus oder oberflächen-antigen, as other registers publish it.
- PolandAdjupanrixGlaxoSmithKline Biologicals S.A.
- DenmarkAdjupanrixGlaxoSmithKline Biologicals S.A.
- BelgiumAdjupanrixGlaxoSmithKline Biologicals
- IcelandAdjupanrixGlaxoSmithKline Biologicals S.A.*
- FinlandAdjupanrixGlaxoSmithKline Biologicals SA
- CzechiaADJUPANRIXGlaxoSmithKline Biologicals S.A., Rixensart
- IrelandAdjupanrix suspension and emulsion for emulsion for injection. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)GlaxoSmithKline Biologicals S.A.
- NetherlandsAdjupanrix, (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals, suspensie en emulsie voor emulsie voor injectieGlaxoSmithKline Biologicals S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/baf4314a-3eb7-4edc-8d3c-6e7889559614 GET /v1/drugs/baf4314a-3eb7-4edc-8d3c-6e7889559614?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": null,
"packaging": "05909991452339 ¦ Rp ¦ EU/1/20/1484/002 ¦ 138800\n1 amp.-strzyk. 0,5 ml ¦ 1 igła \n05909991452353 ¦ Rp ¦ EU/1/20/1484/001 ¦ 138801\n1 amp.-strzyk. 0,5 ml\n05909991452377 ¦ Rp ¦ EU/1/20/1484/004 ¦ 138802\n5 amp.-strzyk. 0,5 ml ¦ 5 igieł \n05909991452384 ¦ Rp ¦ EU/1/20/1484/003 ¦ 138803\n5 amp.-strzyk. 0,5 ml\n05909991452346 ¦ Rp ¦ EU/1/20/1484/005 ¦ 138804\n10 amp.-strzyk. 0,5 ml\n05909991452360 ¦ Rp ¦ EU/1/20/1484/006 ¦ 138805\n10 amp.-strzyk. 0,5 ml ¦ 10 igieł",
"substance": null,
"common_name": "Czterowalentna szczepionka przeciw grypie (rekombinowana, przygotowana w hodowli komórkowej)",
"pl_product_id": "100445839",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about influenza, inaktiviert, spalt/split virus oder oberflächen-antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.